BIIB Biogen Inc.

Biogen to Report Third Quarter 2016 Financial Results on October 26, 2016

Biogen Inc. (NASDAQ:BIIB) today announced it will report third quarter 2016 financial results on Wednesday, October 26, 2016, before the financial markets open.

Following the release of the financials, the Company will host a live webcast where Biogen management will discuss the financial results, at 8:30 am ET. To access the live webcast, please go to the investor relations section of Biogen’s website at www.biogen.com/investors. Following the live webcast, an archived version of the call will be available at the same URL, for one month.

About Biogen

Through cutting-edge science and medicine, Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological, autoimmune and rare diseases. Founded in 1978, Biogen is one of the world’s oldest independent biotechnology companies and patients worldwide benefit from its leading multiple sclerosis and innovative hemophilia therapies. For more information, please visit www.biogen.com. Follow us on Twitter.

EN
14/09/2016

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Biogen Inc.

 PRESS RELEASE

Biogen and Stoke Therapeutics Present Data that Further Support the Di...

Biogen and Stoke Therapeutics Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting —Long-term Phase 1/2a and open label extension (OLE) data for zorevunersen on top of standard of care anti-seizure medicines (ASMs) demonstrate durable seizure reductions, including increases in seizure-free days, in addition to improvements in cognition, behavior and quality of life— —Propensity score weighted analysis comparing the effects of zorevunerse...

Biogen Inc. - September 2025 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch